Literature DB >> 15574788

Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses.

Isabelle Bourgault Villada1, Micheline Moyal Barracco, Isabelle Bourgault Villada1, Micheline Moyal Barracco, Marianne Ziol, Aude Chaboissier, Nathalie Barget, Sophie Berville, Bernard Paniel, Eric Jullian, Thierry Clerici, Bernard Maillère, Jean Gérard Guillet.   

Abstract

Cell-mediated immunity directed against human papillomavirus 16 (HPV-16) antigens was studied in six patients affected with grade 3 vulvar intraepithelial neoplasia (VIN3, also known as bowenoid papulosis). Five of the patients presented with a chronic and persistent disease that relapsed after destructive treatments. They showed no detectable anti-HPV blood T-cell responses and no T-cell intraepidermal vulvar infiltrate containing both CD4+ and CD8+ lymphocytes. The last patient had a complete clearance of viral lesions, 8 months after disease onset and 2 months after electrocoagulation of <50% of the VIN3 lesions. She showed high frequency anti-E6 and anti-E7 effector blood T cells by ex vivo ELISpot-IFNgamma assay before clinical regression. Immunohistochemical study of her vulvar biopsy revealed a marked dermal infiltrate containing a majority of CD4+ T lymphocytes and an epidermal infiltrate made up of both CD4(+) and CD8(+) T cells. This seems to be the first evidence of an association between spontaneous regression of VIN3 lesions and HPV-specific T-cell responses detectable in the blood. Hence, an increase of HPV-specific effector T lymphocyte responses by vaccine-based therapeutic strategies might be useful to clear the lesions in bowenoid papulosis disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15574788     DOI: 10.1158/0008-5472.CAN-04-2455

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  A genome-wide association study identifies two new cervical cancer susceptibility loci at 4q12 and 17q12.

Authors:  Yongyong Shi; Li Li; Zhibin Hu; Shuang Li; Shixuan Wang; Jihong Liu; Chen Wu; Lin He; Jianfeng Zhou; Zhiqiang Li; Ting Hu; Yile Chen; Yao Jia; Shaoshuai Wang; Li Wu; Xiaodong Cheng; Zhijun Yang; Ru Yang; Xiong Li; Kecheng Huang; Qinghua Zhang; Hang Zhou; Fangxu Tang; Zhilan Chen; Jian Shen; Jie Jiang; Hu Ding; Hui Xing; Shulan Zhang; Pengpeng Qu; Xiaojie Song; Zhongqiu Lin; Dongrui Deng; Ling Xi; Weiguo Lv; Xiaobing Han; Guangshi Tao; Lixing Yan; Zhedong Han; Zhuang Li; Xiaoping Miao; Shandong Pan; Yuanming Shen; Hui Wang; Dan Liu; Ee Gong; Zheng Li; Limei Zhou; Xiaomei Luan; Chuping Wang; Qian Song; Sufang Wu; Hongbin Xu; Jiawei Shen; Fulin Qiang; Gang Ma; Li Liu; Xiaojun Chen; Jibin Liu; Jiangping Wu; Yan Shen; Yang Wen; Minjie Chu; Jiang Yu; Xiaoxia Hu; Yujuan Fan; Hongying He; Yanming Jiang; Zhiying Lei; Cui Liu; Jianhua Chen; Yuan Zhang; Cunjian Yi; Shuangyun Chen; Wenjin Li; Daowen Wang; Zehua Wang; Wen Di; Keng Shen; Dongxin Lin; Hongbing Shen; Youji Feng; Xing Xie; Ding Ma
Journal:  Nat Genet       Date:  2013-06-30       Impact factor: 38.330

2.  Tailored immunotherapy for HPV positive head and neck squamous cell cancer.

Authors:  Neil Gildener-Leapman; John Lee; Robert L Ferris
Journal:  Oral Oncol       Date:  2013-10-11       Impact factor: 5.337

3.  Patterns of CD8 T-cell epitopes within the human papillomavirus type 16 (HPV 16) E6 protein among young women whose HPV 16 infection has become undetectable.

Authors:  Mayumi Nakagawa; Kevin H Kim; Anna-Barbara Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

4.  CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix.

Authors:  Samantha Seresini; Massimo Origoni; Luigi Caputo; Flavia Lillo; Renato Longhi; Simone Vantini; Anna Maria Paganoni; Maria Pia Protti
Journal:  Immunology       Date:  2010-06-02       Impact factor: 7.397

5.  A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers.

Authors:  Angelika B Riemer; Derin B Keskin; Guanglan Zhang; Maris Handley; Karen S Anderson; Vladimir Brusic; Bruce Reinhold; Ellis L Reinherz
Journal:  J Biol Chem       Date:  2010-07-08       Impact factor: 5.157

6.  Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.

Authors:  Ricardo Rosales; Mario López-Contreras; Carlos Rosales; Jose-Roberto Magallanes-Molina; Roberto Gonzalez-Vergara; Jose Martin Arroyo-Cazarez; Antonio Ricardez-Arenas; Armando Del Follo-Valencia; Santiago Padilla-Arriaga; Miriam Veronica Guerrero; Miguel Angel Pirez; Claudia Arellano-Fiore; Freddy Villarreal
Journal:  Hum Gene Ther       Date:  2014-12       Impact factor: 5.695

Review 7.  Immune therapy for human papillomaviruses-related cancers.

Authors:  Ricardo Rosales; Carlos Rosales
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 8.  Immunoprevention of human papillomavirus-associated malignancies.

Authors:  Joshua W Wang; Chein-Fu Hung; Warner K Huh; Cornelia L Trimble; Richard B S Roden
Journal:  Cancer Prev Res (Phila)       Date:  2014-12-08

9.  Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins.

Authors:  I Bourgault Villada; M Moyal Barracco; S Berville; M L Bafounta; C Longvert; V Prémel; P Villefroy; E Jullian; T Clerici; B Paniel; B Maillère; J Choppin; J G Guillet
Journal:  Clin Exp Immunol       Date:  2009-07-30       Impact factor: 4.330

10.  Induction of CD4-independent E7-specific CD8+ memory response by heat shock fusion protein.

Authors:  Hongwei Liu; Bill H Wu; Gerry J Rowse; Peter C R Emtage
Journal:  Clin Vaccine Immunol       Date:  2007-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.